News|Articles|November 19, 2026

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

Listen
0:00 / 0:00

Key Takeaways

  • A 700-mg every-6-week maintenance schedule is now permitted across all six EU cemiplimab indications, replacing the prior restriction to adjuvant high-risk CSCC only.
  • The EU label allows 15–30-minute infusions for 350 mg every 3 weeks after a well-tolerated initial 30-minute infusion, improving infusion suite throughput and patient convenience.
SHOW MORE

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

The European Commission has approved an alternative dosing schedule for cemiplimab (Libtayo) of 700 mg every 6 weeks after 12 weeks of administration at 350 mg every 3 weeks, along with shorter infusions of the 350-mg dose, across all 6 approved indications in skin, lung, and cervical cancers.¹

The decision followed a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use issued in October 2026.² Previously, the 700-mg every-6-week option was available in the European Union (EU) only for adjuvant treatment of patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence; all other indications used 350 mg every 3 weeks. The new schedule halves dosing frequency after the first 12 weeks.¹

Under the approved regimen, patients first receive cemiplimab at 350 mg by 30-minute intravenous (IV) infusion every 3 weeks for 12 weeks, followed by 700 mg by 30-minute IV infusion every 6 weeks. Patients who continue on 350 mg every 3 weeks and whose first 30-minute infusion at that dose was well tolerated may receive subsequent infusions over 15 to 30 minutes. The approval drew on pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation, together with safety and efficacy data from across cemiplimab’s clinical program.

“By offering an every-6-week maintenance schedule, and potentially halving infusion times for the every-three-week dose, we can help ease the burden of frequent clinic visits and longer infusion times for patients, while giving healthcare providers greater flexibility,” Israel Lowy, MD, PhD, who is the Senior Vice President and Oncology Clinical Development Unit Head at Regeneron Pharmaceuticals, stated in the news release.

Which cemiplimab indications does the approval cover?

In CSCC, the schedule covers cemiplimab monotherapy for adult patients with metastatic or locally advanced disease who are not candidates for curative surgery or radiation, as well as adjuvant monotherapy for adult patients whose CSCC carries a high risk of recurrence following surgery and radiation. It also extends to monotherapy for adult patients with locally advanced or metastatic basal cell carcinoma whose disease progressed on, or who could not tolerate, a hedgehog pathway inhibitor.

In non–small cell lung cancer (NSCLC), the schedule applies to first-line monotherapy for adult patients whose tumors express PD-L1 in at least 50% of tumor cells, and to first-line cemiplimab plus platinum-based chemotherapy for adults whose tumors express PD-L1 in at least 1% of tumor cells. In both NSCLC settings, patients must have no EGFR, ALK, or ROS1 aberrations and have either metastatic disease or locally advanced disease for which definitive chemoradiation is unsuitable. The final indication is monotherapy for adult patients with recurrent or metastatic cervical cancer who progressed on or after platinum-based chemotherapy.

What is the mechanism of action of cemiplimab?

Cemiplimab, a fully human monoclonal antibody, binds the PD-1 immune checkpoint receptor on T cells. This binding has been shown to prevent cancer cells from exploiting the PD-1 pathway to dampen T-cell activation. The agent is approved in at least 1 indication in more than 30 countries.

How has the 700-mg every-6-week schedule been studied?

The phase 3 C-POST trial (NCT03969004) evaluated a regimen that included cemiplimab at 700 mg every 6 weeks.3,4 C-POST enrolled patients with CSCC at high risk of recurrence after surgery and postoperative radiation therapy and randomly assigned them 1:1 to adjuvant cemiplimab or placebo. Following a protocol amendment on June 29, 2021, cemiplimab was given at 350 mg IV every 3 weeks for 12 weeks, then 700 mg every 6 weeks for up to 36 weeks, for a total of up to 48 weeks. Disease-free survival (DFS) was the primary end point, and secondary end points included freedom from locoregional and distant recurrence, as well as safety.

At a median follow-up of 24 months, DFS events occurred in 24 patients in the cemiplimab arm (n = 209) vs 65 patients in the placebo arm (n = 206; HR, 0.32; 95% CI, 0.20-0.51; P < .001). The estimated 24-month DFS rate was 87.1% (95% CI, 80.3%-91.6%) with cemiplimab vs 64.1% (95% CI, 55.9%-71.1%) with placebo.3 Because the every-6-week schedule was introduced by amendment, these results do not establish the efficacy of that schedule separately.

“These data provide compelling evidence of the long-term, durable benefit of adjuvant treatment with Libtayo in high-risk CSCC after surgery and radiation, further supporting [cemiplimab] as a transformative standard of care for these patients,” Danny Rischin, MD, MBBS, FRACP, who is the research lead for head and neck cancer and CSCC in the Department of Medical Oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia, and the lead investigator of C-POST stated in an October 2026 news release on longer-term C-POST data.5

What has changed in EU cemiplimab dosing?

Prior: 700 mg every 6 weeks, after 12 weeks of 350 mg every 3 weeks, was approved in the EU only for adjuvant treatment of high-risk CSCC; other indications used 350 mg every 3 weeks over 30 minutes.²

Current: The European Commission extended the every-6-week option to all 6 EU indications and allowed 15- to 30-minute infusions of 350 mg after a well-tolerated first 30-minute infusion.¹

Next: A US supplemental biologics license application for the schedule is under review, with a decision expected in March 2027.

What is the status of the US dosing application?

In the United States, a supplemental biologics license application for the alternative dosing regimen is under FDA review, with a decision expected in March 2027.¹ The US label already includes 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks for adjuvant treatment of high-risk CSCC, following FDA approval in that setting in October 2025.6

References

1.Libtayo (cemiplimab) approved in the European Union (EU) for extended dosing and faster infusion times across skin, lung and cervical cancer indications. News release. Regeneron Pharmaceuticals, Inc. November 17, 2026. Accessed November 19, 2026. https://www.globenewswire.com/news-release/2026/11/17/3404448/0/en/libtayo-cemiplimab-approved-in-the-european-union-eu-for-extended-dosing-and-faster-infusion-times-across-skin-lung-and-cervical-cancer-indications.html

2.Alternative cemiplimab dosing strategy receives CHMP recommendation in multiple cancer types. OncLive. October 17, 2026. Accessed November 19, 2026. https://www.onclive.com/view/cemiplimab-receives-chmp-recommendation-in-multiple-cancer-types

3.Rischin D, Porceddu S, Day F, et al; C-POST Trial Investigators. Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N Engl J Med. 2025;393(8):774-785. doi:10.1056/NEJMoa2502449. https://www.nejm.org/doi/10.1056/NEJMoa2502449

4.Study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma (C-POST). ClinicalTrials.gov. Accessed November 19, 2026. https://clinicaltrials.gov/study/NCT03969004

5.Libtayo (cemiplimab) longer-term data show increasing and clinically meaningful overall survival benefit with adjuvant treatment in high-risk cutaneous squamous cell carcinoma (CSCC). News release. Regeneron Pharmaceuticals, Inc. October 25, 2026. Accessed November 19, 2026. https://investor.regeneron.com/node/32426/pdf

6.FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma. FDA. October 8, 2025. Accessed November 19, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-adjuvant-treatment-cutaneous-squamous-cell-carcinoma


Related to this article